Search Results
Your search for all items matches 35093 pages
Showing 1 - 50AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative
Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and magnetic resonance imaging (MRI) for breast cancer screening, according to study results that were published in Nature...
Erika Hamilton, MD, on Oral SERDs in Breast Cancer: State of the Science
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, provides a look at “where we stand in 2025” in the field of oral selective estrogen receptor degraders (SERDs) for patients with estrogen receptor–positive, HER2-negative breast cancer. She discusses the first...
utDNA May Help to Personalize Bladder Cancer Treatment
Results of a multi-institutional study published by St-Laurent et al in Science Direct revealed that testing urine-based tumor DNA (utDNA) may help to predict which patients with bladder cancer are at higher risk for recurrence after not responding to first-line treatment. The study analyzed utDNA...
Case 3: Recurrent Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
This is Part 3 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the management of recurrent...
Case 2: High-Risk De Novo Metastatic Hormone-Sensitive Prostate Cancer
This is Part 2 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of high-risk de...
Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens
As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (ARPI) in patients with castration-resistant prostate cancer with extrapelvic soft-tissue metastases...
Case 1: De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer With PTEN Deficiency
This is Part 1 of Targeted Approaches to Metastatic Hormone-Sensitive Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Alicia Morgans, Charles Ryan, and David VanderWeele discuss the treatment of de novo...
HER3-DXd in NSCLC Without EGFR-Activating Mutations
As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with advanced squamous or nonsquamous non–small cell lung cancer (NSCLC) without a...
Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer
Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40, according to the results of a survey. The survey, commissioned by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research...
Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
The 2025 ASCO Annual Meeting has officially concluded. Our sincere thanks to the global oncology community and ASCO for creating such a remarkable forum advancing cancer care. Here we highlight the most impactful updates in genitourinary tumors from this year’s meeting. Kidney Cancer: Long-Term...
Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML
In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...
Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes
As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...
Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests
About one in six tested chemotherapies in sub-Saharan Africa were found to have serious quality defects, according to the results of a study published in The Lancet Global Health. Researchers assessed the appearance, packaging, and labeling of each cancer medication and measured the quantity of...
ASTRO Updates Guideline on Radiation Therapy for High-Grade Diffuse Glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy for adults with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The...
Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal
In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Study Details In the...
Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer
Injection with botulinum toxin (BTX) type A (IncoA) plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA (prostate-specific membrane antigen) tumor uptake in patients with metastatic prostate cancer who were receiving...
Predictive Biomarker Under Study in Colorectal Cancer
Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology. Background Colorectal cancer is the second-leading cause of...
Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing
The Association for Molecular Pathology has introduced best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency testing, according to new guidelines published by Hsiao et al in The Journal of Molecular Diagnostics. Background Homologous...
Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer
In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...
Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...
Breast Cancer: New Study Finds Survivors May Face Lower Risk of Alzheimer Dementia
Breast cancer survivors may have a slightly lower risk of developing Alzheimer dementia compared with cancer-free individuals, according to the results of a study published by Jeong et al in JAMA Network Open. “The risk of Alzheimer dementia is a crucial aspect of overall well-being among breast...
Case 3: Radioligands in Advanced Neuroendocrine Tumor
This is Part 3 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the use of radioligand therapy for advanced...
Case 2: Well-Differentiated Grade 3 Small Bowel Neuroendocrine Tumor
This is Part 2 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment of well-differentiated grade 3...
Case 1: Pancreatic Neuroendocrine Tumor
This is Part 1 of Evolving Treatment Paradigms for Neuroendocrine Tumors, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel Halperin, Jess Maxwell, and Virginia Corbett discuss the treatment pancreatic neuroendocrine...
Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models
A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery. The MYST gene family histone...
Study Finds AI Chatbots Are Vulnerable to Spreading Malicious, False Health Information
While artificial intelligence (AI) large language models (LLMs) hold the promise to help consumers find trustworthy health information, a study assessing the safeguards incorporated into these models has found that they are vulnerable to malicious instruction that converts them into health...
Nearly 50% of All Cancer Deaths Worldwide Attributable to Modifiable Risk Factors
New data reported in The Cancer Atlas, Fourth Edition showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation exposure,...
GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma
A novel immuno–positron-emission tomography (immunoPET) imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, including those under 1 cm, according to the results of a pilot clinical study presented at the...
Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...
Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds
Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...
The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology
Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this position on August 15. Dr. Rolfo will ...
I Was Expecting to Hear I Have Heart Disease, Not Cancer
In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...
W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award
W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...
William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84
William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84. Dr. Wood was the J.B. Whitehead Professor and Chair of the Department of Surgery at Emory University School of Medicine from 1991 to 2009. He chaired the 1990 U.S. National...
Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74
The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...
Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting
The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...
Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035
The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The...
Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer
Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...
Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions
Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...
ASCO and Medicaid: Advocacy In Action
The Association for Clinical Oncology (ASCO) is actively engaged in advocacy to protect Medicaid access for millions of Americans. Members can support ASCO’s Medicaid advocacy efforts through the ACT Network. In 2025, ASCO has partnered with other health-care organizations and engaged with...
National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The National Comprehensive Cancer Network® (NCCN®) has announced a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision-making and policy in cancer care and are the...
ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...
In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer
In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction...
ACS Study Focuses on Effects of Medicaid Expansion in Low-Income Older Adults With Cancer
A recent study by researchers at the American Cancer Society (ACS) showed that Medicaid expansion was associated with an increase in Medicaid coverage, early-stage cancer diagnoses, and improved 2-year survival among individuals aged 65 or older who were diagnosed with cancer. They believe these...
Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer
Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) vs the current standard of care (chemotherapy ± bevacizumab) may live...
Case 3: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 and PIK3CA Mutations
This is Part 3 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 64-year-old postmenopausal woman...
Case 2: Second-Line Treatment of ER-Positive, HER2-Negative Metastatic Breast Cancer and ESR1 D538G Mutation After Progression on CDK4/6 Inhibitor
This is Part 2 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 67-year-old postmenopausal woman...
